Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 82, Issue 6, Pages 740-744Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.clpt.6100402
Keywords
-
Categories
Ask authors/readers for more resources
The MF59 adjuvant has been included in a licensed influenza vaccine for a decade. Hence, we have a significant amount of clinical data to establish its potency and safety. We can now reassess our early preclinical studies and determine whether or not they were useful to predict human responses. The main lesson learned is that mouse models can be valuable, but one must ask the right questions and the models must be used appropriately.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available